Genentech has announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and efficacy of lampalizumab. Lampalizumab, as reported here in July 2016, is an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). It was designed to inhibit Complement Factor D, a protein best known for its role in reducing inflammation.
Further dosing in patients will be interrupted until the results from a second Phase III study are evaluated. “While this result is disappointing”, said Sandra Horning, M.D., chief medical officer and head of Global Product Development, “we will continue to evaluate results from Spectri to get a clearer understanding of the data as we await the results of our second Phase III study, Chroma, anticipated in November.”
Source: Press Release